Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Aug 5;118(6):625-31.
doi: 10.1161/CIRCULATIONAHA.107.759191. Epub 2008 Jul 21.

Tumor necrosis factor-alpha and mortality in heart failure: a community study

Affiliations

Tumor necrosis factor-alpha and mortality in heart failure: a community study

Shannon M Dunlay et al. Circulation. .

Abstract

Background: Tumor necrosis factor-alpha (TNFalpha), an inflammatory cytokine, was reported to be elevated in trials of heart failure (HF) with reduced ejection fraction (EF) and associated with mortality. Whether this is true for HF with preserved EF is unknown, and community data are lacking. We evaluated the distribution of TNFalpha, its association with baseline characteristics and mortality, and its benefit in assessing risk in community HF patients.

Methods and results: Olmsted County residents with active HF from July 2004 to March 2007 (n=486; mean age, 76.7 years; EF > or =50%, 55%) were prospectively recruited. Clinical characteristics and TNFalpha were measured. Elevated TNFalpha (more than the assay limit of normal of 2.8 pg/mL) was present in 143 (29%). Higher TNFalpha was associated with decreased creatinine clearance, nonsmoking status, anemia, and greater comorbidity (P(trend)<0.05 for all). Mortality increased with increasing TNFalpha (P=0.016), with 1-year mortality estimates of 16%, 18%, 23%, and 32% from the lowest to highest quartile, respectively. After adjustment for age, sex, and EF, the hazard ratios for death were 1.24, 1.37, and 1.90 from the second to the highest TNFalpha quartile, respectively (P(trend)=0.007). TNFalpha contributed to risk assessment as indicated by increases in the area under the receiver operating characteristic curves in all models examined (P<0.05 for all). Results did not differ by EF (P=0.60 interaction term of TNFalpha and EF).

Conclusions: TNFalpha was elevated in a large portion of community HF patients, was associated with a large decrease in survival, and provided a significant incremental increase in risk assessment above established indicators. TNFalpha is useful for risk assessment in HF patients with preserved and reduced EF.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Tumor Necrosis Factor α (TNFα) levels by Creatinine Clearance and Hemoglobin. Caption: TNFα levels by creatinine clearance (A) and hemoglobin (B) are shown. Each box displays the median, 25th percentile, and 75th percentile values; horizontal bars represent 1.5 times the interquartile range. No.= number
Figure 1
Figure 1
Tumor Necrosis Factor α (TNFα) levels by Creatinine Clearance and Hemoglobin. Caption: TNFα levels by creatinine clearance (A) and hemoglobin (B) are shown. Each box displays the median, 25th percentile, and 75th percentile values; horizontal bars represent 1.5 times the interquartile range. No.= number
Figure 2
Figure 2
Kaplan-Meier Mortality Curves by TNFα Quartile. Caption: Mortality during follow-up was analyzed by TNFα quartile. HF= heart failure

References

    1. Torre-Amione G. Immune activation in chronic heart failure. American Journal of Cardiology. 2005;95(suppl):3C–8C. - PubMed
    1. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. Circulation. 2006;113:e72–e75. - PubMed
    1. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. New England Journal of Medicine. 1990;323:236–41. - PubMed
    1. Dutka DP, Elbown JS, Delamere F, Shale DJ, Morris GK. Tumour necoris factor alpha in severe congestive heart failure. British Heart Journal. 1993;70:141–3. - PMC - PubMed
    1. Deswal A, Peterson NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the vesnarinone trial (VEST) Circulation. 2001;103:2055–9. - PubMed

Publication types

Substances